Moore Capital Management, LP Cyma Bay Therapeutics, Inc. Transaction History

Moore Capital Management, LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Nov 14, 2019	SELL	$5.12 - $7.21 $128,000 - $180,250	-25,000 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$8.16 - $13.42 $204,000 - $335,500	25,000 New	25,000 $332,000
Q2 2018 Aug 14, 2018	SELL	$10.66 - $14.38 $533,000 - $719,000	-50,000 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$5.95 - $8.26 $297,500 - $413,000	50,000	50,000 $403,000

1.82M

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

Get notified when there are updates to the investment portfolio of Moore Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Moore Capital Management, LP with notifications on news.